

# SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number  
EP 15 82 9426

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	EP 0 978 287 A1 (MITSUI CHEMICALS INC [JP]) 9 February 2000 (2000-02-09) * abstract, paragraphs [0004] and [0005], [0012]-[0028] and claims *	1-9, 12-15	INV. C07K16/28 A61K39/00
X	WO 2011/073180 A1 (ABLYNX NV [BE]; VERDONCK FRANK [BE]; CORNELIS SIGRID [BE]; STAELENS ST) 23 June 2011 (2011-06-23) * abstract, p. 2 line 15 - p. 9 line 18, p. 24 line 12 - p. 35 line 29, examples 1-6 and claims *	1-9, 12-15	
X	US 8 551 477 B1 (CROFT MICHAEL [US] ET AL) 8 October 2013 (2013-10-08) * abstract, column 1 line 28 - column 6 line 9, examples 1-10 and claims *	1-9, 12-15	
X	WO 2007/133290 A2 (GENENTECH INC [US]; MARTIN FLAVIUS [US]) 22 November 2007 (2007-11-22) * abstract, p. 2 line 7 - p. 13 line 38, examples 1-8 and claims *	1-9, 12-15	
			TECHNICAL FIELDS SEARCHED (IPC)
			A61K C07K
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search Munich		Date of completion of the search 29 November 2017	Examiner Hermann, Patrice
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

1

EPO FORM 1503 03.82 (P04N04)

## CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing claims for which payment was due.

☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due and for those claims for which claims fees have been paid, namely claim(s):

☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due.

## LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

☐ All further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for all claims.

☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

☐ Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

☒ None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims:

1-6, 9(completely); 7, 8, 12-15(partially)

# **LACK OF UNITY OF INVENTION** **SHEET B**

Application Number  
EP 15 82 9426

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-6, 9(completely); 7, 8, 12-15(partially)

Invention 1 relates to a OX40L inhibitor in general for use in preventing or treating an autoimmune disease, more particularly wherein said OX40L inhibitor is an anti-CD252 monoclonal antibody comprising the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 5, 6, and 7 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 12, 13 and 14 respectively.

---

2. claims: 10(completely); 7, 8, 12-15(partially)

Invention 2 relates to an anti-CD40L (anti-CD252) monoclonal antibody for use in the prevention or treatment of autoimmune disease, more particularly when the anti-CD252 monoclonal antibody comprises the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 19, 20 and 21 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 26, 27 and 28 respectively.

---

3. claims: 11(completely); 7, 8, 12-15(partially)

Invention 3 relates to an anti-CD40L (anti-CD252) monoclonal antibody for use in the prevention or treatment of autoimmune disease, more particularly when the anti-CD252 monoclonal antibody comprises the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 33, 34 and 35 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOs: 40, 41 and 42 respectively.

---

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 15 82 9426

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-11-2017

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0978287	A1	09-02-2000	CA 2272605 A1	01-04-1999
			EP 0978287 A1	09-02-2000
			JP 3914342 B2	16-05-2007
			JP H11180893 A	06-07-1999
			US 6333035 B1	25-12-2001
			WO 9915200 A1	01-04-1999
-----				
WO 2011073180	A1	23-06-2011	EP 2513145 A1	24-10-2012
			EP 3309176 A1	18-04-2018
			US 2013018175 A1	17-01-2013
			US 2015218281 A1	06-08-2015
			WO 2011073180 A1	23-06-2011
-----				
US 8551477	B1	08-10-2013	US 7291331 B1	06-11-2007
			US 7531170 B1	12-05-2009
			US 7807156 B1	05-10-2010
			US 8101175 B1	24-01-2012
			US 8551477 B1	08-10-2013
			US 8956615 B1	17-02-2015
			US 9873744 B1	23-01-2018
-----				
WO 2007133290	A2	22-11-2007	AR 057253 A1	21-11-2007
			AU 2006343459 A1	22-11-2007
			BR PI0621065 A2	29-11-2011
			CA 2633602 A1	22-11-2007
			CN 101374865 A	25-02-2009
			CR 10069 A	10-10-2008
			EC SP088543 A	30-07-2008
			EP 1973949 A2	01-10-2008
			JP 2009519718 A	21-05-2009
			KR 20080080639 A	04-09-2008
			MA 30153 B1	02-01-2009
			TW 200732349 A	01-09-2007
			US 2009053230 A1	26-02-2009
			US 2010272738 A1	28-10-2010
			WO 2007133290 A2	22-11-2007
			ZA 200804868 B	28-10-2009
-----				